Medical/Pharmaceuticals
AnBogen Therapeutics Receives Approval from U.S. FDA for Phase Ib/II Protocol Amendment for ABT-101
An oral Tyrosine Kinase Inhibitor of HER2 Exon20 Insertion, for the Treatment of Non-Small Cell Lung Cancer TAIPEI, Sept. 13, 2022 /PRNewswire/ -- AnBogen Therapeutics, a clinical-stage biotech company designing and developing precision oncology therapies to improve the life of patients, announ...
2022-09-13 22:00
3259
Turn Biotechnologies launches eTurna™ delivery platform designed specifically to enable nucleic acid therapeutics
The proprietary platform is versatile, equally effective with different cargoes, routes of administration MOUNTAIN VIEW, Calif., Sept. 13, 2022 /PRNewswire/ -- Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines to cure untreatable, age-related conditions, today ann...
2022-09-13 20:38
3275
AO Foundation acquires RIMASYS to advance the surgical education ecosystem of the future
DAVOS, Switzerland and COLOGNE, Germany, Sept. 13, 2022 /PRNewswire/ -- The AO
Foundation and RIMASYS are pleased to announce that they have taken their
strategic partnership to the next level with a full-stake investment by the AO
in RIMASYS.
2022-09-13 18:00
2746
TikoMed's ILB(R) inhibits cell infection by coronaviruses and modulates reactive cytokine release from microglia in vitro
Adds further support for its broad-spectrum mechanism of action following other recent TBI, ALS and tropical virus studies VIKEN, Sweden, Sept. 13, 2022 /PRNewswire/ -- TikoMed today announced the inclusion in bioRxiv* of an in vitro study evaluating the ability of the company's lead drug candid...
2022-09-13 16:08
2311
SmartFuture's White-label Remote Patient Monitoring Platform goes global
SINGAPORE, Sept. 13, 2022 /PRNewswire/ -- SmartFuture's white-label Remote Patient Monitoring (RPM) platform is now being deployed successfully in 11 countries, includingSingapore, Malaysia, other ASEAN countries, India and most recently, inthe United States. According to Sumit Khemani, CEO, "...
2022-09-13 16:03
4515
Microtech to unveil implantable microsensor technology at 34th Transcatheter Cardiovascular Therapeutics (TCT) annual meeting
TEL AVIV, Israel, Sept. 13, 2022 /PRNewswire/ -- Microtech, a wholly owned subsidiary of Medinol, Inc., a leader in global MedTech research and development, announced that its implantable microsensor platform will be presented at the34th Transcatheter Cardiovascular Therapeutics (TCT), the annua...
2022-09-13 09:11
2525
CStone announces China's NMPA has accepted and granted priority review to the supplemental new drug application (sNDA) for sugemalimab in the treatment of patients with relapsed or refractory extranodal natural killer/T-cell lymphoma (R/R ENKTL)
* This is the third supplemental new drug application (NDA) that CStone has submitted for sugemalimab after the prior two for stage III and IV non-small cell lung cancer. Sugemalimab has the potential to become the world's first immuno-oncology therapy to be approved for patients with relapsed ...
2022-09-13 08:02
5404
Transcenta Releases Encouraging Interim Safety and Efficacy Data of the TST001 (Osemitamab) and Chemotherapy Combination Expansion Cohort for First Line Claudin18.2 Positive Gastric Cancer at ESMO Congress 2022
* In first line treatment of advanced or metastatic G/GEJ cancer, early interim data of the first 15 patients with measurable disease receiving the combination of TST001 (Osemitamab) with CAPOX demonstrated a partial response rate of 73.3% and a disease control rate of 100% per RECIST1.1. * B...
2022-09-13 08:00
3606
Starpharma presents compelling data in Prostate Cancer at ESMO
MELBOURNE, Australia, Sept. 13, 2022 /PRNewswire/ -- Cabazitaxel (Jevtana, Sanofi) is a market leading chemotherapy for the treatment of advanced prostate cancer (mCRPC). Developed by Australian biotech company Starpharma, DEP® cabazitaxel is a patented, highly water soluble dendrimer nanopartic...
2022-09-13 06:28
2332
NCCN's New Patient Guidelines for Marginal Zone Lymphoma Help Patients and Caregivers Better Understand a Rare Form of Blood Cancer
An evidence-based, expert consensus resource, available for free at NCCN.org/patientguidelines, helps people understand a rare and complex cancer type PLYMOUTH MEETING, Pa., Sept. 13, 2022 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®) has published new NCCN Guidelines for P...
2022-09-13 00:35
2369
Aldatu Biosciences Adds Another Outbreak Disease to Pandemic Preparedness Portfolio
BOSTON, Sept. 13, 2022 /PRNewswire/ -- Aldatu Biosciences, a biotechnology company developing molecular diagnostic assays and products based on gold standard real-time PCR, today announced it has been awarded a$3 Million Direct-to-Phase II Small Business Innovation Research (SBIR) grant from the ...
2022-09-13 00:33
2189
DarwinHealth Publication Reports Step-by-Step Protocol for its Tumor Checkpoint-Based, Compound-to-Clinic (C2C) Cancer Drug Discovery Pipeline: Elucidates a Patient-to-Model-to-Patient (PMP) Roadmap for Precision- and Mechanism-Based Identification and Clinical Validation of Novel, Investigational and FDA-Approved Therapeutic Agents Targeting Tumor Regulatory Architecture
NEW YORK, Sept. 13, 2022 /PRNewswire/ -- DarwinHealth, Inc., ( www.DarwinHealth.com) a New York-based biotechnology and cancer drug discovery company announces theSeptember 9, 2022 online publication in Current Protocols (Wiley Science) of their proprietary cancer drug discovery and validation pi...
2022-09-13 00:26
3227
EpiVax Secures Additional Funding from FDA for Immunogenicity Risk Assessment for Biosimilar Products
PROVIDENCE, R.I., Sept. 13, 2022 /PRNewswire/ -- EpiVax, Inc. ("EpiVax") is pleased to announce the award of a two-year,$2 million grant from the FDA's Office of Center for Drug Evaluation and Research (CDER) to validate a method for immunogenicity risk assessment of host cell proteins (HCP) for ...
2022-09-13 00:24
2888
MASSIMO CALAFIORE APPOINTED AS NEW LIMACORPORATE CEO
VILLANOVA DI SAN DANIELE DEL FRIULI, Udine, Italy, Sept. 13, 2022 /PRNewswire/ -- LimaCorporate, a leading global orthopedic manufacturer focused on digital innovation and patient-tailored devices, today announces thatMassimo Calafiore has been appointed by the Board of Directors asthe new Chief ...
2022-09-13 00:22
3146
Himalaya Therapeutics Announces Interim Phase 2 Results for Mecbotamab vedotin (HTBA3011)
* Preliminary observations in Non-Small Cell Lung Cancer ("NSCLC") support advancing to the registrational stage of the trial; anticipate full interim data set in 4Q'22 * Undifferentiated Pleomorphic Sarcoma ("UPS") and osteosarcoma will advance to Phase 2, part 2 enrollment, which is anticip...
2022-09-12 23:32
3325
Brain Navi Biotechnology Announced Partnership with Distributor, Medtreq Medical Equipment, to enter the Middle East and Egypt with NaoTrac Neurosurgical Robot
HSINCHU, Sept. 12, 2022 /PRNewswire/ -- Brain Navi, the leading surgical robot manufacture inTaiwan, announced a strategic partnership with distributor, Medtreq Medical Equipment, to expand the distribution of the Surgical Navigation Robot, NaoTrac, throughout the region of GCC region,Jordan, Egy...
2022-09-12 08:31
3943
First patient enrolled in Erectile Dysfunction prospective randomized study with SELUTION SLR
GENEVA, Switzerland, Sept. 10, 2022 /PRNewswire/ -- An 82-year-old Taiwanese
man has become the first patient to be enrolled in the initial Erectile
Dysfunction (ED) randomized clinical trial (RCT) involving SELUTION SLR™,
MedAlliance's novel sirolimus-eluting balloon.
2022-09-10 06:00
3860
ESMO 2022 - Great oaks grow from small acorns: oncology is committed to doing its part for sustainability
PARIS, Sept. 10, 2022 /PRNewswire/ -- At ESMO 2022, 9-13 September, Paris, France, the premier cancer congress in Europe, which has gathered 28k participants from 167 countries, many discussions will be around sustainability, prevention and novel approaches which could soon become a reality in t...
2022-09-10 04:46
2750
Prenetics Announces Second Quarter 2022 Financial Results and Raises Full Year Adjusted EBITDA Outlook
* Revenue of US$51.7 million in the second quarter of 2022 * Loss from operations of US$(17.9) million and adjusted EBITDA[1] of US$6.5 million in the same period * Raises full year adjusted EBITDA guidance to the range of US$35 million to US$45 million, with corresponding full year revenue ...
2022-09-09 23:17
6849
MGI Celebrates Grand Opening of Its New State-of-the-Art Demo Lab in Japan
TOKYO, Sept. 9, 2022 /PRNewswire/ -- MGI Tech Co., Ltd. (MGI), a global life science leader and innovator, announced today on its first day of IPO inChina the grand opening of a new demonstration laboratory inTokyo, Japan, enhancing Japanese customers' experience. MGI has been expanding the oper...
2022-09-09 09:00
3534
Week's Top Stories
Most Reposted
DayOne Files Registration Statement for Proposed Initial Public Offering
[Picked up by 277 media titles]
2026-10-06 05:28SMU School of Accountancy launches Applied AI Track for next generation of accounting and finance professionals
[Picked up by 277 media titles]
2026-10-07 11:50Zenika CTO Adrien Nortain Moves Base to Singapore to Strengthen Technical Leadership in Asia
[Picked up by 271 media titles]
2026-10-01 10:00
Vestas Powers Up Vietnam's Clean Energy Ambitions with Two New Projects Under PDP8 Totaling 16 Wind Turbines
[Picked up by 263 media titles]
2026-10-02 16:27
Southeast Asia's China travel map is widening, Traveloka platform data shows
[Picked up by 262 media titles]
2026-10-05 11:51Most Read
MixVio AI Launches Unified Creative Workspace Across 26 AI Generation Routes
2026-10-02 00:30
24046